Vantia Therapeutics, a Southampton, United Kingdom-based pharmaceutical company developing novel, small molecule drugs, has raised £4m (approximately $6.5m) in a Series B funding.
The round was co-led by Novo A/S and SV Life Sciences, with participation from MVM Life Science Partners.
The company intends to use the funds to advance the development of its two clinical candidates, VA106483 for nocturia and VA111913 for dysmenorrhoea, both of which are in Phase II trials.
Formed in 2008 as a spin-out of Ferring Research Ltd’s small molecule R&D, and led by CEO Andrew Crockett since June 2011, Vantia also develops preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.
The company is situated on Southampton Science Park, UK, where it occupies 10,000 sq ft of chemistry and biology facilities.